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Abbreviations used in this pap
ratio; IQR, interquartile range; L
tasis; OR, odds ratio; T1CRC, TRisk stratification for adverse events, such as metastasis to lymph nodes, is based only on
histologic features of tumors. We aimed to compare adverse outcomes of pedunculated vs
nonpedunculated T1 colorectal cancers (CRC).METHODS: We performed a retrospective study of 1656 patients diagnosed with T1CRC from 2000 through
2014 at 14 hospitals in The Netherlands. The median follow-up time of patients was 42.5
months (interquartile range, 18.5–77.5 mo). We evaluated the association between tumor
morphology and the primary composite end point, adverse outcome, adjusted for clinical
variables, histologic variables, resection margins, and treatment approach. Adverse outcome
was defined as metastasis to lymph nodes, distant metastases, local recurrence, or residual
tissue. Secondary end points were tumor metastasis, recurrence, and incomplete resection.RESULTS: Adverse outcome occurred in 67 of 723 patients (9.3%) with pedunculated T1CRCs vs 155 of
933 patients (16.6%) with nonpedunculated T1CRCs. Pedunculated morphology was indepen-
dently associated with decreased risk of adverse outcome (adjusted odds ratio [OR], 0.59; 95%
CI, 0.42–0.83; P [ .003). Metastasis, incomplete resection, and recurrence were observed in
5.8%, 4.6%, and 3.9% of pedunculated T1CRCs vs 10.6%, 8.0%, and 6.6% of nonpedunculated
T1CRCs, respectively. Pedunculated morphology was independently associated with a reducedhip.
er: CRC, colorectal cancer; HR, hazard
N, lymph node; LNM, lymph node metas-
1 colorectal cancer.
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May 2019 Pedunculated vs Nonpedunculated T1CRCs 1113risk of metastasis (adjusted OR, 0.62; 95% CI, 0.41–0.94; P [ .03), incomplete resection
(adjusted OR, 0.57; 95% CI, 0.36–0.91; P [ .02), and recurrence (adjusted hazard ratio, 0.52;
95% CI, 0.32–0.85; P [ .009). Metastasis, incomplete resection, and recurrence did not differ
significantly between low-risk pedunculated vs nonpedunculated T1CRCs (0.8% vs 2.9%, P [
.38; 1.5% vs 0%, P [ .99; 1.5% vs 0%; P [ .99). However, incomplete resection and recurrence
were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs (6.5% vs
12.5%; P [ .007; 4.4% vs 8.6%; P [ .03).CONCLUSIONS: In a retrospective study of patients with T1CRC, we found pedunculated morphology to be
associated independently with a decreased risk of adverse outcome in a T1CRC population at
high risk of adverse outcome. Incorporating morphologic features of tumors in risk assessment
could help predict outcomes of patients with T1CRC and help identify the best candidates for
surgery.Keywords: Colonoscopy; Endoscopic Mucosal Resection; Colon Cancer; Prognostic Factor.See related editorial on page 1035.
The frequency of early colorectal cancer (CRC) hasbeen increasing since the introduction of national
screening programs. In 2015, 48% of detected CRCs in
the Dutch screening program were stage I CRCs, in line
with other Western countries.1–3 T1 colorectal cancer
(T1CRC) without metastasis is the earliest form of stage I
CRC and is defined as tumor growing through the mus-
cularis mucosae into the submucosa without invading
the muscularis propria.4 Lymph node metastasis (LNM)
risk of T1CRC is 8% to 14%.5–12 Therefore, most patients
with T1CRC can be cured with an endoscopic resection.
However, current risk models have insufficient ability to
predict which patients with an endoscopically resected
T1CRC should have additional surgery.13
Complete endoscopic resection of pedunculated
T1CRCs is more feasible compared with non-
pedunculated T1CRCs. In addition, pedunculated T1CRCs
may have a lower metastasis risk compared with non-
pedunculated T1CRCs.9,14–16 In the present study, we
evaluated the association between morphology (pedun-
culated vs nonpedunculated) and adverse outcome.
Methods
Study Design
We performed a multicenter retrospective cohort
study. Patients with T1CRC, defined as tumor growing
through the muscularis mucosae into, but not beyond,
the submucosa,17 diagnosed between January 1, 2000,
and December 31, 2014, in 14 Dutch hospitals (2 aca-
demic and 12 nonacademic), were selected from The
Netherlands Cancer Registry. Electronic medical records
were reviewed. Patients with synchronous CRC,
non–CRC-related death within 1 year, hereditary pre-
disposition for CRC, inflammatory bowel disease, carci-
noid, missing pathology or endoscopy reports, and who
underwent neoadjuvant radiotherapy were excluded. Inaddition, patients without reported morphology in the
endoscopy report were excluded.
Determinant
The determinant of interest was morphology, strati-
fied as pedunculated vs nonpedunculated. Because
closing the snare followed by dehydration and formalin
fixation procedures can alter morphology, morphology
was based on the endoscopist’s judgement. T1CRC was
considered pedunculated in case of presence of a stalk or
Paris Classification 0–Ip was reported. Nonpedunculated
T1CRC included flat or sessile tumors.18–20End Points
The primary composite end point was adverse
outcome, defined as any of the following: LNM, distant
metastasis, local recurrence, or residual tissue. We used
a composite end point rather than only LNM because the
surgical referral rate is known to be higher for patients
with nonpedunculated T1CRCs. Restricting our analysis
to patients treated with surgery (ie, patients with known
N status) therefore would introduce selection bias. The
end point could be reached by both endoscopically and
surgically treated patients, allowing an equal comparison
of pedunculated and nonpedunculated T1CRCs. LNM was
defined as tumor-positive lymph nodes (LNs) in the
surgical specimen. Distant metastasis was defined as
metastasis to extracolonic organs confirmed with imag-
ing or histology. Local recurrence was defined as carci-
noma in biopsy tissue from the anastomosis after
surgery or from the polypectomy scar after endoscopic
resection. Residual tissue was defined as carcinoma in
the surgical specimen after endoscopic resection, irre-
spective of whether endoscopic resection was macro-
scopically complete or not.
Secondary end points included metastasis, recurrence,
and incomplete resection separately. We defined metas-
tasis as LNM for patientswho underwent surgery or distant
metastasis regardless of treatment.Recurrencewasdefined
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treatment. Incomplete resection was defined as residual
tissue in the colectomyspecimenafter secondarysurgeryor
local recurrence regardless of treatment.Current histologic prediction models have insuffi-
cient discriminative ability to identify patients who
benefit from surgical treatment after endoscopic
resection. Although it has been suggested that
pedunculated T1 colorectal cancers (T1CRCs) have a
lower risk for metastasis and incomplete resection as
compared with nonpedunculated T1CRCs, a direct
comparison has not yet been performed and current
risk stratification for surgery is based on histology
only.
Findings
Pedunculated morphology was associated indepen-
dently with a decreased risk for an adverse outcome
(ie, lower risk for lymph node metastasis, distant
metastasis, local recurrence, or residual tissue). The
absolute risk for adverse outcomes in patients with
pedunculated T1CRC was nearly half that of patients
with nonpedunculated T1CRCs (9.3% vs 16.6%,
respectively). In patients with low-risk T1CRC,
defined as the absence of the following criteria: poor
differentiation, deep submucosal invasion, lympho-
vascular invasion, and Rx/R1 resection margins, the
rates of metastasis, incomplete resection, and recur-
rence rates did not differ significantly between
pedunculated vs nonpedunculated morphology.
However, incomplete resection and recurrence rates
were significantly lower for high-risk pedunculated
vs nonpedunculated T1CRCs.
Implications for patient care
Morphology has a promising potential to refine risk
stratification in patients with T1CRC and therefore
should be incorporated in future risk stratification.
This study underlines that the ratio of includedConfounders
Clinical confounders included age, sex, tumor local-
ization (right colon vs left colon vs rectum), and tumor
size.9,13,21–24 The right colon was defined as the colon
proximal to and including the splenic flexure and the
left colon as the colon distal to the splenic flexure
excluding the rectum. Histologic confounders included
lymphovascular invasion (absent vs present), differen-
tiation grade (good or moderate vs poor), and resection
margins (negative [R0] vs not assessable [Rx] vs posi-
tive [R1]). R0 resection was defined as a cancer-free
resection margin irrespective of distance in millime-
ters. In patients treated with primary endoscopy and
secondary surgery, endoscopic resection margins were
used and in patients treated with primary surgery,
surgical resection margins were used. Although invasion
depth is an acknowledged risk factor for stratification of
T1CRCs into low- or high-risk groups, invasion depth
was not included as a confounder because the classifi-
cation for submucosal invasion depth is inherently
different between pedunculated and nonpedunculated
T1CRCs.23,25,26 Treatment approach and LN yield were
considered confounders because surgery decreases
recurrence risk in high-risk T1CRC and a high LN yield
has been associated with a decreased risk for recur-
rence.21,22 Patients were categorized into 3 subgroups:
endoscopic resection, surgical resection with fewer than
10 LNs retrieved, and surgical resection with 10 or
more LNs retrieved. Transanal endoscopic microsurgery
was considered an endoscopic treatment because no
lymphadenectomy was performed.pedunculated and nonpedunculated T1CRCs should
be taken into account when extrapolating the risk for
adverse outcomes as reported in the current litera-
ture to individual patients in clinical practice, and
necessitates adequate reporting of morphology type
in future T1CRC studies.Statistical Analysis
Baseline characteristics were compared between
pedunculated and nonpedunculated T1CRCs using
standard descriptive statistics. In addition, the risk for
adverse outcome, metastasis, recurrence, and incom-
plete resection between low-risk pedunculated and
nonpedunculated T1CRC, and high-risk pedunculated
and nonpedunculated T1CRC, was compared using
descriptive statistics. T1CRCs were classified as high
risk if 1 or more of the following criteria were present:
(1) poor differentiation, (2) deep submucosal invasion
(>1000 mm or sm2–3 for nonpedunculated; Haggitt 4
for pedunculated), (3) lymphovascular invasion, or (4)
Rx/R1 resection margins, in line with current guide-
lines.23,25,26 If all of these criteria were absent, T1CRCs
were classified as low risk. If 1 of the criteria was
unknown and no other high-risk factors were present,
risk status was classified as unknown.We evaluated whether morphology was associated
with adverse outcome using univariable and multivari-
able logistic regression analyses and adjusted for con-
founders in a 4-step approach. First, we adjusted for
clinical factors. Second, we additionally adjusted for
histologic factors (lymphovascular invasion and differ-
entiation grade). In a third step, we additionally adjusted
for resection margins. We chose this approach because
histologic factors were missing in a considerable number
of patients. Fourth, we additionally adjusted for treat-
ment approach. The association between morphology
and the secondary end points metastasis and incomplete
May 2019 Pedunculated vs Nonpedunculated T1CRCs 1115resection was evaluated in the same manner. The asso-
ciation between morphology and recurrence was evalu-
ated with univariable and multivariable Cox regression
analyses, expressed in hazard ratios (HRs) with 95% CI.
We adjusted for the same confounders as the primary
end point and additionally adjusted for LNM because this
is a well-established risk factor for recurrence.4,27 The
follow-up period started at the date of diagnosis and
ended at the date of detection of recurrence, death, or
last follow-up evaluation. We found no violation of the
proportionality of the hazard assumption by examining
the scaled Schoenfeld residuals.
Several confounding variables had missing values.
Multivariate imputation by chained equations (10
imputation data sets, 25 iterations, healthy convergence)
was performed before data analysis (package mice in
R).28 Rubin’s rules were used to pool results across
imputation data sets.29
Statistical analysis was performed using IBM SPSS
Statistics version 24 (SPSS, Inc, Chicago, IL) and R
version 3.2.2 (RStudio, Inc, Boston, MA).
Results
Study Population
We identified 2346 patients diagnosed with T1CRC
between 2000 and 2014 in participating hospitals. Of
these, 1656 patients with a median follow-up time of
42.5 months (interquartile range [IQR], 18.5–77.5 mo)
were eligible for analysis (Figure 1). The cohort con-
sisted of 723 pedunculated T1CRCs (43.7%) followed up
for a median of 45.6 months (IQR, 20.6–80.3 mo), andFigure 1. Study flow chart. T1CRC, T1 colorectal cancer.933 (56.3%) nonpedunculated T1CRCs followed up for a
median of 40.9 months (IQR, 17.2–73.6 mo).
Baseline characteristics of patients with pedunculated
vs nonpedunculated T1CRCs are presented in Table 1.
Compared with patients with nonpedunculated T1CRCs,
patients with pedunculated T1CRCs were younger (69 vs
71 y; P < .001) and more often treated with primary
endoscopy (52.8% vs 27.4%; P < .001). Moreover,
pedunculated T1CRCs more often were located in the left
colon (80.5% vs 44.4%; P < .001) and were smaller (20
vs 23 mm; P < .001). LN yield more often was low (<10
retrieved LNs) in patients with pedunculated T1CRCs
(71.9% vs 54.7%; P < .001). The presence of lympho-
vascular invasion and poor differentiation did not differ
significantly, however, R0 resection was achieved less
often in patients with pedunculated T1CRCs (69.8% vs
75.3%; P ¼ .04). If patients underwent an endoscopic
resection of T1CRC, R0 resection was achieved in 63.7%
of pedunculated vs 46.9% of nonpedunculated T1CRCs.
Adverse Outcome
Adverse outcomes were observed in 13.4% (222 of
1656; 95% CI, 11.8–15.2) of patients. This concerned 93
patients with LNM, 39 with distant metastasis, 33 with
local recurrences, 18 with local and distant metastasis,
and 58 with residual tumor in the surgical specimen
when additional surgery was performed, with 17 pa-
tients having 2 or 3 adverse oncologic events. The me-
dian time to recurrence was 23.1 months (IQR, 10.1–43.2
mo) and did not differ significantly between patients
with pedunculated and nonpedunculated T1CRCs (me-
dian, 19.2 mo; IQR, 10.7–43.7 mo; median, 24.8 mo; IQR,
9.8–43.2 mo; respectively; P ¼ .77).
Adverse outcomes were observed in 9.3% (67 of 723;
95% CI, 7.4–11.6) of patients with pedunculated vs
16.6% (155 of 933; 95% CI, 14.4–19.1) of patients with
nonpedunculated T1CRCs. Adverse outcomes did not
differ significantly between low-risk pedunculated vs
low-risk nonpedunculated T1CRCs (2.3% vs 2.9%; P ¼
.99), however, adverse outcomes were significantly
lower for high-risk pedunculated vs nonpedunculated
T1CRCs (14.0% vs 21.2%; P ¼ .01) (Table 2).
In univariable analysis, pedunculatedmorphology was
associated with a decreased risk for adverse outcome
(unadjusted odds ratio [OR], 0.51; 95% CI, 0.38–0.70; P<
.001). After adjusting for clinical variables, histologic
variables, resection margins, and treatment approach, the
pedunculated morphology remained independently
associated with a decreased risk for adverse outcome
(adjusted OR, 0.59; 95% CI, 0.42–0.83; P ¼ .003).
Metastasis, Incomplete Resection, and
Recurrence
Metastasis was observed in 8.5% (141 of 1656; 95%
CI, 7.2–10.0) of patients: 93 with LNM and 57 with
Table 1. Baseline Characteristics of Pedunculated Vs Nonpedunculated T1CRCs
Pedunculated (N ¼ 723) Nonpedunculated (N ¼ 933) P value
Age, y, mean (SD) 69 (63–76) 71 (64–78) <.001
Unknown 0 2
Male sex, N (%) 410 (56.7) 516 (55.3) .57
Tumor localization, N (%)
Right colon 23 (3.2) 244 (26.2) <.001
Left colon 581 (80.5) 415 (44.5)
Rectum 118 (16.3) 273 (29.3)
Unknown 1 1
Treatment approach, N (%)
Primary endoscopy 382 (52.8) 256 (27.4) <.001
Secondary surgery 220 (30.4) 190 (20.4)
Primary surgery 121 (16.7) 487 (52.2)
Number of retrieved lymph nodes, N (%)a
<10 lymph nodes 240 (71.9) 367 (54.7) <.001
10 lymph nodes 94 (28.1) 304 (45.3)
Unknown 7 6
Tumor size, mm, median (IQR) 20 (15–30) 23 (15–39) <.001
Unknown 59 67
Lymphovascular invasion, N (%)
Present 58 (17.5) 63 (14.9) .33
Absent 274 (82.5) 361 (85.1)
Unknown 391 509
Differentiation grade, N (%)
Good/moderate 477 (94.5) 715 (95.5) .42
Poor 28 (5.5) 34 (4.5)
Unknown 218 184
Invasion depth in nonpedunculated T1CRCs, N (%)
Superficial (SM1 or <1000 mm) - 132 (31.4) -
Deep (SM2/3 or 1000 mm) - 289 (68.6)
Unknown - 512
Invasion depth in pedunculated T1CRCs, N (%) - -
Superficial (Haggitt 1–3) 411 (86.3) -
Deep (Haggitt 4) 65 (13.7) -
Unknown 247
Resection margins, N (%)b .04
R0 492 (69.8) 682 (75.3)
Rx 85 (12.1) 95 (10.5)
R1 128 (18.2) 129 (14.2)
Unknown 18 27
IQR, interquartile range; T1CRC, T1 colorectal cancer.
aPresented for patients who underwent surgery.
bIn patients treated with primary endoscopy: endoscopic resection margins; in patients treated with secondary surgery: endoscopic resection margins; in patients
treated with primary surgery: surgical resection margins.
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in 6.5% (108 of 1656; 95% CI, 5.4–7.9) of patients: 50
with local recurrence, 57 with residual tissue when a
secondary surgery was performed, and 1 with both local
recurrence and residual tissue. Recurrences were
observed in 5.4% (90 of 1656; 95% CI, 4.4–6.7) of pa-
tients: 39 with distant metastasis, 33 with local re-
currences, and 18 with local and distant metastasis.
Details on metastasis, incomplete resection, and recur-
rence stratified per treatment approach are shown in
Supplementary Table 1.
Metastasis, incomplete resection, and recurrence
were observed in 5.8% (42 of 723; 95% CI, 4.3–7.8),
4.6% (33 of 723; 95% CI, 3.2–6.4), and 3.9% (28 of 723;
95% CI, 2.6–5.6) of patients with pedunculated vs 10.6%
(99 of 933; 95% CI, 8.7–12.8), 8.0% (75 of 933; 95% CI,6.4–10.0), and 6.6% (62 of 933; 95% CI, 5.2–8.5) of pa-
tients with nonpedunculated T1CRCs, respectively.
Metastasis, incomplete resection, and recurrence did not
differ significantly between low-risk pedunculated vs
nonpedunculated T1CRCs (0.8% vs 2.9%, P ¼ .38; 1.5%
vs 0%, P ¼ .99; and 1.5% vs 0%, P ¼ .99; respectively).
However, incomplete resection and recurrence rates
were significantly lower for high-risk pedunculated vs
nonpedunculated T1CRCs (6.5% vs 12.5%, P ¼ .007;
4.4% vs 8.6%, P ¼ .03; respectively) (Table 2).
In univariable analysis, pedunculated morphology
was associated with a decreased risk for metastasis
(unadjusted OR, 0.52; 95% CI, 0.36–0.76; P < .001),
decreased risk for incomplete resection (unadjusted OR,
0.55; 95% CI, 0.36–0.83; P ¼ .005), and decreased risk
for recurrence (unadjusted HR, 0.54; 95% CI, 0.35–0.85;
Table 2. Risk for Adverse Outcome, Metastasis, Incomplete Resection, and Recurrence in Pedunculated Vs Nonpedunculated
T1CRCs Stratified for Risk Status
Pedunculated Nonpedunculated
P valuePatients, n Events, n (%) Patients, n Events, n (%)
Low risk 130 35
Adverse outcome 3 (2.3) 1 (2.9) .99
Metastasis 1 (0.8) 1 (2.9) .38
Incomplete resection 2 (1.5) 0 (0) .99
Recurrence 2 (1.5) 0 (0) .99
High risk 293 513
Adverse outcome 41 (14.0) 109 (21.2) .01
Metastasis 24 (8.2) 61 (11.9) .10
Incomplete resection 19 (6.5) 64 (12.5) .007
Recurrence 13 (4.4) 44 (8.6) .03
Unknown risk group 300 385
Adverse outcome 23 (7.7) 45 (11.7) .08
Metastasis 17 (5.7) 37 (9.6) .06
Incomplete resection 12 (4.0) 11 (2.9) .41
Recurrence 13 (4.3) 18 (4.7) .83
NOTE. T1CRCs were classified as high-risk T1CRCs if 1 or more of the following criteria were present: (1) poor differentiation, (2) deep submucosal invasion
(>1000 mm or sm2–3 for nonpedunculated T1CRCs, Haggitt 4 for pedunculated T1CRC), (3) lymphovascular invasion, (4) Rx/R1 resection margins. When all these
factors were absent, it was considered a low-risk T1CRC. The unknown risk group concerns T1CRCs in which 1 of these histologic features was unknown and no
high-risk factors were present.
T1CRC, T1 colorectal cancer.
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variables, resection margins, and treatment approach,
the pedunculated morphology remained independently
associated with a decreased risk for metastasis (adjusted
OR, 0.62; 95% CI, 0.41–0.94; P ¼ .03) and incomplete
resection (adjusted OR, 0.57; 95% CI, 0.36–0.91; P ¼ .02)
(Table 3). Moreover, after adjusting for the same vari-
ables plus LNM, the pedunculated morphology remained
independently associated with a decreased risk for
recurrence (adjusted HR, 0.52; 95% CI, 0.32–0.85; P ¼
.009) (Table 3).Discussion
This study presents a large-scale comparison of
adverse outcomes between T1CRCs with different
morphology. We observed an almost 2-fold lower
adverse outcome rate in patients with pedunculated
compared with nonpedunculated T1CRCs (9.3% vs
16.6%), and pedunculated T1CRCs had a favorable
outcome even after adjusting for clinicopathologic con-
founders. We observed no significant differences in
adverse outcomes between low-risk pedunculated and
nonpedunculated T1CRCs. Our study thereby does not
support that traditionally defined low-risk sessile
T1CRCs must undergo surgery because of an intrinsically
aggressive behavior.
The favorable outcome in patients with pedunculated
T1CRCs implies that the reported risk of adverse out-
comes in T1CRC cohorts is influenced by the ratio of
included pedunculated and nonpedunculated T1CRCs.
We should take this into account when extrapolating therisk for adverse outcomes as reported in the current
literature to individual patients in clinical practice.
Moreover, this necessitates adequate reporting of
morphology type together with stratified adverse
outcome rates in future T1CRC studies. In addition, the
combined positive predictive value of current histologic
markers is as low as 10% to 15%, which means that 85%
to 90% of patients undergo major surgery without any
clinical benefit.13 Our results suggest that morphology
may refine risk stratification, helping to expand the
proportion of T1CRC patients treated with endoscopic
resection.
Although patient numbers were low in the low-risk
nonpedunculated T1CRC group, our study suggests that
risk for adverse outcomes is similar in pedunculated and
nonpedunculated low-risk T1CRCs. A low percentage of
low-risk nonpedunculated T1CRCs is in line with previ-
ous studies.9,30 Several factors have contributed to this.
First, if only 1 of the high-risk factors was absent, pa-
tients could not be classified as low risk. Adverse
outcome rates in the unknown group are between the
rates found in the low- and high-risk groups, suggesting
that the actual number of patients with low-risk T1CRC
was higher. Second, achieving a R0 resection is more
difficult in nonpedunculated compared with peduncu-
lated T1CRCs.31 Finally, current risk stratification is
limited. Our study group recently developed a new
model to better predict the need for adjuvant surgery in
patients with pedunculated T1CRCs.32 With this model, a
higher number of pedunculated T1CRCs could be clas-
sified as low risk compared with conventional models
(68% vs 35%). This may be a first step toward a T1CRC
risk assessment taking morphology into account.
Table 3. Risk for Adverse Outcome, Metastasis, Incomplete Resection, and Recurrence in 723 Pedunculated T1CRCs Vs 933 Nonpedunculated T1CRCs
P, n (%) NP, n (%) OR (95% CI) P value
Adverse outcome,a
222 events in 1656 T1CRCs (13.4%)
67 (9.3) 155 (16.6) Unadjusted 0.51 (0.38–0.70) <.001
Adjusted for clinical factorsb 0.53 (0.38–0.73) <.001
Adjusted for clinical and histologic high-risk factorsc 0.49 (0.35–0.69) <.001
Adjusted for clinical and histologic high-risk factors and marginsd 0.49 (0.35–0.69) <.001
Adjusted for clinical and histologic high-risk factors, margins, and treatmente 0.59 (0.42–0.83) .003
Metastasis,f
141 events in 1656 T1CRCs (8.5%)
42 (5.8) 99 (10.6) Unadjusted 0.52 (0.36–0.76) <.001
Adjusted for clinical factorsb 0.52 (0.35–0.78) .002
Adjusted for clinical and histologic high-risk factorsc 0.48 (0.32–0.72) <.001
Adjusted for clinical and histologic high-risk factors and marginsd 0.48 (0.32–0.72) <.001
Adjusted for clinical and histologic high-risk factors, margins, and treatmente 0.62 (0.41–0.94) .03
Incomplete resection,g
108 events in 1656 T1CRCs (6.5%)
33 (4.6) 75 (8.0) Unadjusted 0.55 (0.36–0.83) .005
Adjusted for clinical factorsb 0.56 (0.36–0.87) .01
Adjusted for clinical and histologic high-risk factorsc 0.55 (0.35–0.86) .009
Adjusted for clinical and histologic high-risk factors and marginsd 0.54 (0.34–0.85) .008
Adjusted for clinical and histologic high-risk factors, margins, and treatmente 0.57 (0.36–0.91) .02
HR (95% CI)
Recurrence,h
90 events in 1656 T1CRCs (5.4%)
28 (3.9) 62 (6.6) Unadjusted 0.54 (0.35–0.85) .007
Adjusted for clinical factorsb 0.60 (0.37–0.96) .03
Adjusted for clinical and histologic high-risk factorsc 0.57 (0.36–0.92) .02
Adjusted for clinical and histologic high-risk factors and marginsd 0.58 (0.36–0.92) .02
Adjusted for clinical and histologic high-risk factors, margins, and LNMi 0.61 (0.38–0.99) .05
Adjusted for clinical and histologic high-risk factors, margins, LNM, and treatmentj 0.52 (0.32–0.85) .009
P, pedunculated T1CRC; NP, nonpedunculated T1CRC; T1CRC, T1 colorectal cancer.
aDefined as lymph node metastasis, distant metastasis, local recurrence, residual tissue in the colectomy specimen when secondary surgery was performed, or a combination of these outcomes.
bAdjusted for clinical factors: age (continuous), sex (male vs female), location (left colon vs right colon vs rectum), and tumor size (continuous).
cAdjusted for clinical factors and histologic factors: lymphovascular invasion (absent vs present) and differentiation grade (good/moderate vs poor).
dAdjusted for clinical factors, histologic factors, and resection margins (R0 vs Rx vs R1).
eAdjusted for clinical and histologic factors, resection margins, and treatment group (endoscopy vs surgery with <10 retrieved LNs vs surgery with 10 retrieved LNs).
fDefined as lymph node metastasis or distant metastasis.
gDefined as local recurrence after endoscopic or surgical treatment, or residual tissue in the colectomy specimen when a secondary surgery was performed.
hDefined as distant metastasis, local recurrence, or both (after endoscopic or surgical treatment).
iAdjusted for clinical and histologic factors, resection margins, and the presence of LNM.
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comes between pedunculated and nonpedunculated
T1CRCs. A systematic review published in 2005
regarding histologic risk factors and unfavorable out-
comes of patients with T1CRCs found a significant dif-
ference in recurrence and metastasis in pedunculated vs
nonpedunculated T1CRCs of 0.4% (1 of 238) vs 6.2% (4
of 64) and 0.8% (5 of 595) vs 3.6% (13 of 357),
respectively. No difference in LNM rate was observed
(9.7% [12 of 124] vs 10.5% [17 of 162]).9 This study,
however, reviewed several small nonconsecutive co-
horts. In addition, no adjustment for confounders was
performed and treatment approach was not taken into
account. A more recent population-based study including
411 patients with T1CRC diagnosed between 1982 and
2011, reported a 5-year cumulative recurrence rate of
5.2% for pedunculated and 6.3% for nonpedunculated
T1CRCs (P ¼ .66).33 However, this comparison was
based on only 15 recurrences vs 90 recurrences in our
study. In addition, inclusion bias may have occurred
because only endoscopic benign-appearing T1CRCs were
included. A study of the Scottish Surgical Research Group
on 485 patients with T1CRCs, which were identified
through the screening program between 2000 and 2012,
found no significant difference in adverse outcomes be-
tween pedunculated and nonpedunculated T1CRCs after
adjustment for confounders.34 However, this study only
included patients who underwent endoscopic resection
(followed by segmental resection or not), which may
have led to exclusion of nonpedunculated high-risk
T1CRCs unfit for endoscopic resection in particular,
leading to an underestimation of adverse outcomes in
the nonpedunculated T1CRC group.
This study had some limitations. Adequate histologic
diagnosis of pedunculated T1CRC is challenging.35,36 A
recent histologic review of a subgroup of 128 pedun-
culated T1CRCs from our cohort by pathologists with
special expertise in gastrointestinal pathology showed
that approximately 10% of cases were overstaged (ie,
T1CRC diagnosis was revised as pseudo-invasion or
high-grade dysplasia).37 This may underestimate the
adverse outcomes of pedunculated T1CRCs in our
cohort. However, our previous study did not evaluate
the percentage of missed T1CRCs diagnosed histologi-
cally as premalignant lesions. In addition, pseudo-
invasion and biopsy-related displaced epithelium
simulating malignancy also have been described in
nonpedunculated T1CRCs, which might balance the
potential underestimation in pedunculated T1CRCs.38
Finally, differentiating T1CRC from its precursor le-
sions is an up-to-date challenge and our cohort reflects
daily clinical practice.36 Because of the retrospective
design, another limitation of this study was that some
variables had a large number of missing data. As a result,
we had to classify a relatively large number of T1CRCs
as having an unknown risk status (41%). To minimize
bias introduced by missing data in the regression anal-
ysis, we performed multiple imputations. Furthermore,we performed the regression analysis in a stepwise
approach, in which we first adjusted for clinical vari-
ables with a low missing rate followed by adjustment for
histologic variables with a higher missing rate.
In conclusion, pedunculated morphology was associ-
ated independently with a decreased risk for adverse
outcomes and the absolute risk for adverse outcomes in
patients with pedunculated T1CRCs was nearly half that
of patients with nonpedunculated T1CRCs. In patients
with low-risk T1CRCs, rates of metastasis, incomplete
resection, and recurrence rates did not differ signifi-
cantly between pedunculated vs nonpedunculated
morphology. However, incomplete resection and recur-
rence rates were significantly lower for high-risk
pedunculated vs nonpedunculated T1CRCs. Our results
suggest that morphology has a promising potential to
refine risk stratification in patients with T1CRCs and
encourage incorporation of morphology in risk stratifi-
cation. Furthermore, our study underlines that the ratio
of included pedunculated and nonpedunculated T1CRCs
should be taken into account when extrapolating the risk
for adverse outcomes as reported in the current litera-
ture to individual patients in clinical practice and ne-
cessitates adequate reporting of morphology in future
T1CRC studies.
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Supplementary Table 1. Adverse Outcomes in Pedunculated and Nonpedunculated T1CRCs Stratified Between Primary
Endoscopy, Secondary Surgery, and Primary Surgery
Overall (N ¼ 1656) Pedunculated (N ¼ 723) Nonpedunculated (N ¼ 933)
Total, n Events, n (%) Total, n Events, n (%) Total, n Events, n (%)
Primary endoscopy
Recurrence 638 382 256
Local 21 7 14
Distant 10 5 5
Local þ distant 11 6 5
Total 42 (6.6) 18 (4.7) 24 (9.4)
Secondary surgery
Recurrence 410 220 190
Local 5 2 3
Distant 8 3 5
Local þ distant 3 0 3
LNM 34 19 15
Residual disease 58 18 40
Total 97 (23.7) 39 (17.7) 58 (30.5)
Primary surgery
Recurrence 608 121 487
Local 7 0 7
Distant 21 5 16
Local þ distant 4 0 4
LNM 59 6 53
Total 83 (13.7) 10 (8.3) 73 (15.0)
Overall 1656 222 (13.4) 723 67 (9.3) 933 155 (16.6)
LNM, lymph node metastasis; T1CRC, T1 colorectal cancer.
May 2019 Pedunculated vs Nonpedunculated T1CRCs 1120.e1
